Search

Search Constraints

You searched for: Author/Creator Fowler, Nathan

Search Results

1. 90Y‐ibritumomab tiuxetan radiotherapy as first‐line therapy for early stage low‐grade B‐cell lymphomas, including bulky disease. (8th July 2014)

2. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. (11th September 2015)

3. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. (6th April 2017)

4. Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma. Issue 5 (May 2014)

5. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. (2nd August 2017)

6. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Issue 2 (28th January 2020)

7. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. (18th June 2014)

8. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients. Issue 6 (17th April 2020)

9. Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). (22nd May 2018)

10. Frontline antibiotic therapy for early‐stage Helicobacter pylori‐negative gastric MALT lymphoma. Issue 6 (6th March 2019)